Ispinesib

N/A

Report date: 2023/05/06 09:03:00
NME

Base Information

Drug NameIspinesib
Drug Alias NameIspinesib mesilate甲磺酸伊匹尼塞艾匹奈司甲磺酸盐Ispinesib mesylate伊匹尼塞甲磺酸盐 +[11] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionKinesin-like protein 1 inhibitors
TargetsKinesin-like protein 1
Therapy Area/IndicationsSkin MelanomaSolid tumoursMyelodysplastic Syndromes +[57] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[7] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesCytokinetics Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesGlaxosmithkline PlcNational Cancer InstituteCytokinetics Inc
Active IndicationsN/A
Inactive IndicationsSkin MelanomaSolid tumoursMyelodysplastic Syndromes +[57] 

Other Information

ATC CodeN/A
Related LinksKEGG